ArticleHepatology international2026
Clonal hematopoiesis of indeterminate potential and metabolic dysfunction-associated steatotic liver disease: Korean biopsy cohort.
Article in Hepatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
BACKGROUND &
aimsClonal hematopoiesis of indeterminate potential (CHIP) has emerged as a contributor to age-related diseases; however, its clinical relevance to metabolic liver disease remains to be established. This study investigated the association between CHIP and metabolic dysfunction-associated steatotic liver disease (MASLD) severity in a Korean biopsy cohort.
methodsWe conducted a prospective analysis of 486 individuals who underwent liver biopsy and whole genome sequencing between 2014 and 2023. CHIP status was defined by pathogenic somatic mutations in known driver genes with a variant allele frequency ≥2%. Histological assessment was performed using the NASH-CRN scoring system. Logistic regression was used for cross-sectional associations, and Cox proportional hazards models were applied for fibrosis progression outcomes.
resultsAmong 427 eligible participants (median age 56 years), 37 (8.7%) harbored pathogenic CHIP mutation, predominantly DNMT3A (n=8) and TET2 (n=6). CHIP prevalence did not differ significantly across histological categories: no steatotic liver disease (10.9%), metabolic dysfunction-associated steatotic liver (6.5%), and metabolic dysfunction-associated steatohepatitis (10.9%; p=0.269). No clinical or histological variable was consistently associated with CHIP across definitions in adjusted or unadjusted analyses. Over a median 28-month follow-up, fibrosis progression occurred in 28 of 287 patients with serial assessments; no significant association with CHIP status was observed (HR 0.67, 95% CI 0.16-2.84; p=0.582).
conclusionsIn this biopsy-based cohort, CHIP was not significantly associated with hepatic histology severity or fibrosis progression. Given the limited number of CHIP carriers and progression events, clinically meaningful associations cannot be excluded and larger, longer-term longitudinal studies are warranted.
Indexed as
Identifiers
42658470What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.